Author

Gurkamal S. Chatta

Roswell Park Comprehensive Cancer CenterORCID 0000-0002-3154-9042Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:clustering· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

Anmbreen JamrozeiD· 2 shared Dean G. TangiD· 2 shared Han Yu· 2 shared Igor J. PuzanoviD· 2 shared Jason S. KirkiD· 2 shared Kent L. NastiukiD· 2 shared Kevin LiniD· 2 shared Wen Jess LiiD· 2 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Anmbreen JamrozeORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Increasing Cancer Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival

Xiaozhuo Liu, Anmbreen Jamroze, Eduardo Cortes, Yibing Ji, Kathy Zhao, Faming Zhao, Julian Ho, Yang Seagle Liu, Elai Davicioni, Shan Wu, Wen Jess Li, Felix Yi-Chung Feng, Joshi J. Alumkal, Daniel Eidelberg Spratt, Christopher J. Sweeney, , Dean G. Tang

This study quantifies cancer stemness in prostate cancer across progression stages, showing its association with therapy resistance, poor survival, and lineage plasticity.

Molecular Cancer · Oct 27, 2026Peer-reviewedCancer Biology

Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study validate BCL-2 as a target across heterogeneous CRPC subtypes

Anmbreen Jamroze, Xiaozhuo Liu, Surui Hou, Wen Jess Li, Han Yu, Amanda Tracz, Justine J. Jacobi, Qiuhui Li, Kent L. Nastiuk, Xin Chen, Jiaoti Huang, Kevin Lin, Mingyu Liu, Changmeng Cai, Yue Lu, , Dean G. Tang

This study validates BCL-2 as a therapeutic target in CRPC by showing its upregulation under AR inhibition and demonstrating efficacy of BCL-2 inhibitors in preclinical and clinical models.

Signal Transduction and Targeted Therapy · May 1, 2026Peer-reviewedCancer Biology